![[Toyota Times] From Strengthening Foundations to Boosting Productivity - Toyota Focuses on Break-Even Volume](https://businessfortnight.com/wp-content/uploads/2025/11/Toyota-Times-From-Strengthening-Foundations-to-Boosting-Productivity-Toyota-218x150.jpg "[Toyota Times] From Strengthening Foundations to Boosting Productivity – Toyota Focuses on Break-Even Volume")
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology firm innovating next-generation cell and gene therapies utilizing its proprietary gene circuit platform, as we speak introduced that on October 27, 2022, the compensation committee of Senti Bio’s board of administrators granted to 9 new staff inventory choices to buy an mixture of 200,200 shares of the Company’s frequent inventory with a per share train value of $2.39. These awards had been made beneath the Company’s 2022 Inducement Equity Plan (the Plan).
The above-described awards had been every granted as an inducement materials to the workers coming into into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and had been granted pursuant to the phrases of the Plan. The Plan was adopted by the Company’s board of administrators on August 5, 2022.
About Senti Bio
Our mission is to create a brand new technology of smarter medicines that outmaneuver complicated ailments utilizing novel and unprecedented approaches. To accomplish this, we’re constructing an artificial biology platform that will allow us to program next-generation cell and gene therapies with what we consult with as Gene Circuits. These Gene Circuits, that are created from novel and proprietary combos of DNA sequences, are designed to reprogram cells with organic logic to sense inputs, compute selections and reply to their mobile environments. We intention to design Gene Circuits to enhance the intelligence of cell and gene therapies as a way to improve their therapeutic effectiveness, precision, and sturdiness in opposition to a broad vary of ailments that standard medicines don’t readily deal with.
Our artificial biology platform makes use of off-the-shelf chimeric antigen receptor pure killer (CAR-NK) cells, outfitted with Gene Circuit applied sciences, to focus on notably difficult liquid and stable tumor oncology indications. Our lead improvement candidate is SENTI-202 for the therapy of acute myeloid leukemia (AML). Additional CAR-NK merchandise embody SENTI-301 for the therapy of hepatocellular carcinoma (HCC) and SENTI-401 for the therapy of CEACAM5-expressing stable tumors, together with colorectal most cancers (CRC). We have additionally demonstrated the breadth of our Gene Circuits in different modalities and ailments exterior of oncology and have executed partnerships with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.
Find extra data at sentibio.com
Follow us on Linkedin: Senti Biosciences
Follow us on Twitter: @SentiBio
